JPWO2023023065A5 - - Google Patents
Info
- Publication number
- JPWO2023023065A5 JPWO2023023065A5 JP2024509374A JP2024509374A JPWO2023023065A5 JP WO2023023065 A5 JPWO2023023065 A5 JP WO2023023065A5 JP 2024509374 A JP2024509374 A JP 2024509374A JP 2024509374 A JP2024509374 A JP 2024509374A JP WO2023023065 A5 JPWO2023023065 A5 JP WO2023023065A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- lymphoma
- seq
- polypeptide
- cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163234001P | 2021-08-17 | 2021-08-17 | |
| US63/234,001 | 2021-08-17 | ||
| US202163275714P | 2021-11-04 | 2021-11-04 | |
| US63/275,714 | 2021-11-04 | ||
| PCT/US2022/040478 WO2023023065A1 (en) | 2021-08-17 | 2022-08-16 | Inducible cytokine prodrug and pd-1/pd-l1 combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534062A JP2024534062A (ja) | 2024-09-18 |
| JP2024534062A5 JP2024534062A5 (https=) | 2025-08-25 |
| JPWO2023023065A5 true JPWO2023023065A5 (https=) | 2025-08-25 |
Family
ID=85239682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024509374A Pending JP2024534062A (ja) | 2021-08-17 | 2022-08-16 | 誘導性サイトカインプロドラッグ及びｐｄ－１／ｐｄ－ｌ１併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240216505A1 (https=) |
| EP (1) | EP4387649A4 (https=) |
| JP (1) | JP2024534062A (https=) |
| AU (1) | AU2022331261A1 (https=) |
| CA (1) | CA3228964A1 (https=) |
| TW (1) | TW202320838A (https=) |
| WO (1) | WO2023023065A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| WO2024248490A1 (ko) * | 2023-05-30 | 2024-12-05 | 아주대학교산학협력단 | Pd-l1을 표적으로 하는 키메라 항원 수용체 및 이를 발현하는 t 세포 치료제 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080167238A1 (en) * | 2001-12-21 | 2008-07-10 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| CA3100005A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| US20210130430A1 (en) * | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| BR112022009110A2 (pt) * | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
-
2022
- 2022-08-16 JP JP2024509374A patent/JP2024534062A/ja active Pending
- 2022-08-16 WO PCT/US2022/040478 patent/WO2023023065A1/en not_active Ceased
- 2022-08-16 AU AU2022331261A patent/AU2022331261A1/en active Pending
- 2022-08-16 CA CA3228964A patent/CA3228964A1/en active Pending
- 2022-08-16 EP EP22859046.9A patent/EP4387649A4/en active Pending
- 2022-08-17 TW TW111131042A patent/TW202320838A/zh unknown
-
2024
- 2024-02-13 US US18/440,816 patent/US20240216505A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | First-in-human phase I study of the OX40 agonist MOXR0916 in patients with advanced solid tumors | |
| JP7493569B2 (ja) | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 | |
| Reichert | Antibodies to watch in 2010 | |
| US20200277398A1 (en) | Humanized antibodies against ceacam1 | |
| JP2020516240A5 (https=) | ||
| CN108026173A (zh) | 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症 | |
| US20260053963A1 (en) | Radioconjugates targeting cd33 in the treatment of breast cancer | |
| KR20240153575A (ko) | Dll3을 표적화하는 암 치료 | |
| US20240216505A1 (en) | Inducible cytokine prodrug and pd-1/pd-l1 combination therapy | |
| JP2021525770A (ja) | がんの治療での使用のためのｃｃｒ５阻害剤 | |
| Shang et al. | Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake | |
| Elez et al. | Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study | |
| WO2021160151A1 (zh) | 抗pd-1抗体在治疗肿瘤中的用途 | |
| JPWO2023023065A5 (https=) | ||
| WO2022218264A1 (en) | Combination therapies for treating cancer | |
| WO2020123477A1 (en) | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist | |
| Balibegloo et al. | Development and clinical application of bispecific antibody in the treatment of colorectal cancer | |
| CN113747897B (zh) | 喹啉衍生物与抗体联合治疗软组织肉瘤 | |
| KR20260028011A (ko) | Egfr에 이상이 있는 비소세포 폐암 대상체를 위한 치료 방법 | |
| CN114127315A (zh) | 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法 | |
| US12539340B2 (en) | Radioconjugates targeting CD33 in the treatment of cancers | |
| JP7802667B2 (ja) | 腫瘍治療のための二重特異性融合タンパク質 | |
| TW202207982A (zh) | 可活化之抗ctla-4抗體之給藥及投與 | |
| US20250326847A1 (en) | Activatable anti-ctla4 antibodies for treating cancer | |
| EP4660203A1 (en) | Pharmaceutical combination of anti-alpha v beta 3 antibody and anti-pd-1 antibody |